IL-34 anticorps (Biotin)

N° du produit ABIN2660792

Détail du produit anti-IL-34 anticorps (Biotin)

Antigène: IL-34 (IL34) (Interleukin 34 (IL34))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IL-34 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Clone: E033B8

Isotype: IgG2a lambda

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur IL-34

Antigène: IL-34 (IL34) (Interleukin 34 (IL34))

Autre désignation: IL-34 (IL34 Produits)

Synonymes: anticorps C16orf77, anticorps IL-34, anticorps 2010004A03Rik, anticorps AI593503, anticorps C18H16ORF77, anticorps interleukin 34, anticorps IL34, anticorps Il34

Sujet: Human IL-34 shares a sequence identity of 99.6 % , 72 % and 71 % with chimpanzee, rat, and mouse IL-34, respectively, on the amino acid level. The IL-34 gene is syntenic in the human, chimpanzee, rat, and mouse genomes. IL-34 has no apparent consensus structural domain or motif, and does not share sequence homology with M-CSF, nevertheless, it binds to the CSFR. These two cytokines are not identical in biological activity and signal activation. IL-34 and CSF show an equivalent ability to support cell growth or survival. However, these cytokines are differing in their ability to induce the production of chemokines (MCP-1 and eotaxin-2) in primary macrophages, the morphological change in TF-1-fms cells, and the migration of J774A.1 cells. The use of monoclonal antibodies against the CSFR suggests differential domain binding of the receptor to IL-34 and CSF and as a result, different bioactivities and signal activation kinetics/strength are produced for these cytokines.

Pathways: Signalisation RTK